-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Weight management for overweight or obese people can be used to help them reach a healthy weightPrescription weight loss medications can also be part of a person's weight management program, but they have a considerable risk of side effectsIn a 2016 article in the American Medical Journal, a team of doctors from Harvard Medical School reviewed the FDA-approved anti-obesity drug's findings that side effects include dizziness, nausea, constipation, insomnia, dry mouth and vomitingYong-Hee Kim, a professor in the Department of Bioengineering at Seoul's Hanyang University in, explains: "The anti-obesity drugs being developed limit calorie intake by acting on the gastrointestinal tract or central nervous systemHowever, most of these drugs have little effect and have serious side effectsKim's latest research focuses on using the genetic code of cells to improve weight loss and avoid side effects associated with anti-obesity drugsinterfere with gene expressionIn their study, Kim and colleagues used crispR interference (CRISPRi), an improved CRISPR gene-editing toolTraditional CRISPR tries to permanently alter the genetic code, unlike CRISPRi, which interferes with gene expression by inhibiting the production of proteinsIn a previous study, Kim developed a way to provide genetic modifiers to white fat cells or fat cellsIn the latest study, published in the journal Genome Research, the team passed CRISPRi components to 99 percent of cells in a cell culture model using short peptides specifically connected to white fat cellsdoi: 10.1101/gr.246900.118the protein that the researchers wanted to target was fatty acid binding protein 4 (FABP4)This protein is abundant in white fat and plasma and plays an important role in sugar and insulin metabolism, and is a major cause of diseases related to obesity and type 2 diabetesA previous study in the journal Science Translational Medicine showed that reducing LEVELs of FABP4 in diabetic mice could improve blood sugar levels, as well as fat and insulin metabolismUsing Kim's team's CRISPRi technology, researchers were able to reduce the expression level of FABP4 by up to 60 percentthe next, the team used mice with obesity and diabetes to inject them twice a week with peptides and targeted CRISPRi for up to six weeksDuring this time, the mice lost about 20 percent of their body weight and reduced inflammation and insulin resistanceSignificant changes in food intake were not recorded during treatment, indicating that weight loss was not due to a decrease in eatingbut the researchers also stressed that there is still a long way to go, from mouse models to real-life patient transformation studiesIn addition, the study was small, with only five mice per sample groupHowever, the findings pave the way for further research to treat obesity from a different perspective from traditional pharmaceutical methodsReferences:1' Cangene therapy be the solution to obesity and diabetes?
[2] Diabetes, obesity: Is gene editing the answer?